Current therapies and new developments in NASH
Jean‐François Dufour, Quentin M. Anstee, Elisabetta Bugianesi, Stephen A. Harrison, Rohit Loomba, Valérie Paradis, Herbert Tilg, Vincent Wai‐Sun Wong, Shira Zelber‐Sagi
Abstract
Non-alcoholic steatohepatitis is becoming the most important aetiology for advanced liver disease. There has been important progress in the field in recent years and the complexity of the pathophysiology of NASH is better understood. Multiple non-invasive circulating and imaging biomarkers have been tested. The importance of lifestyle has been recognised and several drugs are being tested in clinical trials. This review addresses the challenges that healthcare professionals face in the management of NASH patients.
Topics & Concepts
SteatohepatitisIntensive care medicineMedicineClinical trialDiseaseFatty liverNonalcoholic steatohepatitisBioinformaticsPathologyBiologyNonalcoholic fatty liver diseaseLiver Disease Diagnosis and TreatmentDiet, Metabolism, and DiseaseLiver Diseases and Immunity